MetaCap

Aquestive Therapeutics Inc. Company Profile

NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.46-0.245 (-6.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Aquestive Therapeutics at a glance

Aquestive Therapeutics Inc. (NASDAQ: AQST) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Warren, NJ. Aquestive Therapeutics is led by Mr. Daniel Barber and employs about 147 people. The company's shares have traded publicly since 2018.

At a market capitalization of $434.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001398733, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Aquestive Therapeutics do?

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
Aquestive Therapeutics Inc.
Ticker
NASDAQ: AQST
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel Barber
Employees
147
Headquarters
184 Liberty Corner Road, Warren, NJ, United States
Phone
908 941 1900
IPO year
2018
Market cap
$434.88M
SEC CIK
0001398733

Companies similar to Aquestive Therapeutics

AQST peer companies
CompanyPrice% ChgMarket capCompare
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs AQST
EOLSEvolus Inc.6.52-6.86%$431.55Mvs AQST
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs AQST
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs AQST
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs AQST
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs AQST
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs AQST
ARVNArvinas Inc.6.46-4.15%$423.03Mvs AQST

Related